Analytical Data
-
Gene name
IL-2
- Application
-
Alternative Names
IL2RA;Interleukin-2 receptor subunit alpha
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P60568
-
Expression Region
21-153aa
-
AA Sequence
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT
-
Molecular Weight
41.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-2 (IL-2) is a key cytokine that plays a crucial role in the immune response, particularly in the proliferation and activation of T cells. It was first discovered in the late 1970s and has since been recognized for its therapeutic potential in various diseases, including cancer and autoimmune disorders. Due to its significant role in immune regulation, research on recombinant IL-2 has gained momentum, especially in the context of immunotherapy. Recombinant DNA technology has enabled the production of high-purity IL-2 for both research and clinical applications. This has opened avenues for investigating its use as an adjuvant in cancer vaccination, enhancing the efficacy of anti-tumor responses by promoting T cell expansion and activity. Moreover, IL-2 has been utilized in combination therapies to synergize with other immune-modulating agents. However, its clinical use is limited by adverse effects such as vascular leak syndrome and dose-dependent toxicity. As a result, ongoing research aims to develop safer IL-2 variants, optimize dosing regimens, and explore novel delivery methods to maximize its therapeutic benefits while minimizing side effects. Investigations into the mechanisms of action of IL-2 at the cellular and molecular levels are also being conducted to better understand its role in immune responses. Overall, the study of recombinant IL-2 continues to be a significant area of interest, contributing to advancements in immunotherapy and the development of novel treatment strategies for cancer and other immune-related conditions.
